本報(bào)道最初發(fā)表于Endpoints News。請(qǐng)點(diǎn)擊這里查看原文
RTW Investments is making a licensing deal with a China biotech for an antibody that’s being developed for two related autoimmune conditions called Graves’ disease and thyroid eye disease.
RTW Investments 正在與一家中國(guó)生物科技公司達(dá)成一項(xiàng)許可協(xié)議，涉及一款用于治療兩種相關(guān)自身免疫性疾?。ǜ窭追蛩共『图谞钕傧嚓P(guān)眼?。┑脑谘锌贵w。
您已閱讀10%（298字），剩余90%（2620字）包含更多重要信息，訂閱以繼續(xù)探索完整內(nèi)容，并享受更多專屬服務(wù)。